Listen Now

Join us with our guest, Professor Simon Cutting, Ph. D., as we discuss the genetic control of spore formation in Bacillus subtilis, and the research behind the scenes defining Clostridioides difficile in health and environment.

Join us with our guest, Ron Roman, RN, CEO Safety Net as we discuss creating a safe environment, maintaining a safe environment in both healthcare and home. Ron will review Disinfection – what is Clean, Sanitize, Disinfect and Sterilize and how to simplify the terms.

Join us with three C. diff. Survivors - Christine, Alba, and Renata, as they share their personal message with you. We are grateful for their time and for sharing their C. diff. infection experiences with us.

A Symposium specifically developed for Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Distinguished members and keynote speakers provide insight as to what impacts the patient and families on both quality and economic topics, what role leadership plays in creating the right culture for patient-centered care, and how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections. Kathy Bischoff, C. diff. Survivor My C. diff. Journey Renata Johnson, C. diff. Survivor My C. diff. Journey Paul Feuerstadt, MD - review Barbara McGovern, MD, “Treatment of recurrent C. difficile infection with SER-109, an investigational microbiome drug.

A Symposium specifically developed for Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Distinguished members and keynote speakers provide insight as to what impacts the patient and families on both quality and economic topics, what role leadership plays in creating the right culture for patient-centered care, and how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections. Courtney Jones ” Microbiome, Microbiota, and Gut Health.” Denise Cardo, MD “Everyone Has a Role in Antibiotic Awareness.” Larry Kociolek, MD “C. diff. Infections in Pediatrics.” This event was sponsored by Seres Therapeutics. Seres Therapeutics mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics Enjoy the program!

Welcome to the second episode of a special four (4) part series: A Symposium Created For Patients Diagnosed With a C. diff. Infection, Being Treated For a Clostridioides diffiicile infection, Recovering From a Clostridioides difficile Infection and Recurrences with Family Members and Caregivers. Welcome to a Symposium specifically developed for patients, families, and caregivers. The Patient & Family C. diff. Symposium: where a gathering of healthcare professionals, keynote speakers, health advocates, practitioners, educators, are transforming the patient experience, and changing the way people experience C. diff. infections worldwide. Simon Cutting, Ph. D. “Bacillus, and C. diff. Spore Overview. “ Teena Chopra, MD ” Introduction to Infection Prevention.” Doe Kley, RN, MPH “C. diff. Transitioning from Hospital to Home. This event was sponsored by Seres Therapeutics, Seres Therapeutic's mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics Enjoy the presentations by the topic leaders joining us!

The Patient & Family C. diff. Symposium: A gathering of healthcare professionals, keynote speakers, health advocates, practitioners, educators, thought leaders, and patients who are transforming the patient experience, and changing the way people experience C. diff. infections worldwide. Program Presenter: Paul Feuerstadt, MD, FACG Barbara McGovern, MD “Treatment of recurrent C. difficile infection with SER-109, an investigational microbiome drug.” Paul Feuerstadt, MD ” C. diff. Overview – What is a C. diff. Infection?” Sahil Khanna, MBBS, “C. diff. Treatments and FMT Overview. “

Dr. Tamas Haidegger, Ph. D., Associate Professor Obuda University, and Co-founder: HandInscan will be discussing the importance of not only hand-washing but how Hand Hygiene is the top priority in social safety. Hand Hygiene remains the number one infection prevention action individuals can utilize worldwide to prevent the spread of germs and viruses worldwide. Dr. Haidegger will also introduce the research and science behind the HandInScan - an objective hand hygiene control in the medical environment.

Join us with our guest Dr. Robert Carman, Ph. D., Director of Microbiology at TECHLAB, Inc. Dr. Carman's research focuses on Clostridioides difficile (C. diff., C. difficile, CDI). Dr. Carman not only introduces us to the gut microbiome, but explains the details of the environment, the colonies of microorganisms, bacteria, viruses, protozoa, and fungi, that are present in the gastrointestinal tract

Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center. A Four-pronged Threat: Clostridioides difficile Infection (CDI), Antibiotics, the Flu Season, and COVID-19.” - Presented by: Dr. David Lyerly, Co-founder and Chief Science Officer of TECHLAB, Inc. Aerosol Transmission of Pathogens: The Problem and the Solutions. Presented by: Maureen Spencer, RN, M.ED., CIC

Inaugural Dale Gerding Lifetime Achievement Award - Presented by Sahil Khanna, MBBS MS, Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic to Dale Gerding, MD, FACP, FIDSA. Adjunctive Therapy for CDI to Prevent Recurrence: Practical Issues. - Presented by: Dr. Dale Gerding, MD, FACP, FIDSA, Retired Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, and Research Physician at the Edward Hines Jr. VA Hospital. “Antimicrobial Stewardship and Its Impact On C difficile.” - Presented by: Glenn Tillotson, PHD, FIDSA, FRSM,, FCCP, FISC, Senior Consultant, Global ID, Anti-Infective Drug Development, GST Micro LLC. Metronidazole For the Treatment of C. difficile Infections: On the Way Out? - Presented by: Wiep Klaas Smits, Ph. D., Department of Medical Microbiology Leiden University Medical Center

“Introducing a New Disinfection Technology Against C. diff.” Jordan Bastian (Speaker) Infection Preventionist, CloroxPro Clinical and Scientific Affairs, Clorox Company Ibezapolstat Update: Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect? Kevin Garey (Speaker) Chair of the Department of Pharmacy Practice and Translational Research and Professor of Pharmacy Practice, University of Houston College of Pharmacy More Than a CDI: The Revolving Door and a Ray Of Hope. Kathy Bischoff (Speaker) Coordinator, VHA Program, C Diff Foundation Sponsored by ACURX Pharmaceuticals Clorox Healthcare

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 6 Group Discussion I ‘Recent Developments in Diagnosis, Treatment, and Prevention of C. difficile infections In Children.’ GROUP DISCUSSION I Thursday Afternoon Speakers Thomas J. Sandora, MD MPH (Speaker) Associate Professor of Pediatrics : PANELIST, Harvard Medical School : Panel Discussion I Larry Kociolek, MD (Speaker) Attending Physician, Ann & Robert H. Lurie Children’s Hospital Maribeth Nicholson, MD, MPH (Speaker) Assistant Professor of Pediatrics, Vanderbilt University Medical Center. --- 'Introduction to Microbiota and Microbiota Restoration for Recurrent C diff infections' Ken Blount, Ph.D. (Speaker) Chief Scientific Officer, Rebiotix, Inc a Ferring Company ---- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

Caring For a Loved One Diagnosed With a CDI --- “Is this C.diff.? How IBS and IBD Complicate the Diagnosis and Management of Patients With a CDI” Caterina Oneto, MD (Speaker) Clinical Instructor, Division of Gastroenterology, NYU --- “The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 4 --- 'Using a Gut Model to Predict Which Antibiotics Are Associated with CDI and Which Ones Best Treat CDI' Mark Wilcox, MD, FRCPath (Speaker) Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology, Leeds Teaching Hospitals --- Microbiome Therapeutics in 2021: Almost there for C difficile! Sahil Khanna, MBBS MS (Speaker) Professor of Medicine in the Division of Gastroenterology and Hepatology,, Mayo Clinic --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 3 Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis. Florence Sejourne (Speaker) CEO, DA VOLTERRA --- “Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies” Beth Guthmueller (Speaker) Rebiotix, a Ferring Company --- ‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI’ Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics --- We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 2 “The Burden of Clostridioides difficile Infection In the COVID-19 Era” Nicola Petrosillo (Speaker) Head Infection Control and Infectious Disease Service, University Hospital Campus Bio-Medico, Rome, Italy ** Results from ECOSPOR III, a Phase 3 Placebo-Controlled Trial of SER-109, an Investigational Microbiome Therapeutic to Reduce Recurrence of Clostridioides difficile Infection Barbara McGovern, MD (Speaker) VP, Medical Affairs, Seres Therapeutics ** Evidence-Based Hand Hygiene In the Post-COVID World.” Tamas Haidegger (Speaker) Associate Professor, Óbuda University ** We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021. Episode 1 Paul Feuerstadt, MD, FACG, AGAF introduce the C Diff Foundation and provide an overview of a C. difficile infection. Simon M. Cutting, Ph.D. will present: What Makes Us Susceptible to a C. difficile Infection? We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.

Join us with our guests from GoodNature, a Seres Therapeutics program; April Garcia, Site Manager of GoodNature Irvine California, and two GoodNature donors who will share their experiences. They will discuss the who, what, and how in donating poop to potentially support C. diff patients. With microbiome therapeutics on the forefront, it will be an educational discussion.

Join Us With our guest, Sahil Khanna, M.B.B.S., M.S. as we discuss the exciting times of Microbiome Restoration For C. difficile infections and how we are almost there! Dr. Khanna will be introducing the gut microbiome, the research, development, and importance of the microbiome in our health along with the microbiome therapeutics in clinical trials with validated safety and efficacy.